ClinicalTrials.gg

Program

clesitamig

Also written as “ALPS12” and “RO7616789”.

Its studies are mostly in Small Cell Lung Carcinoma, led by Hoffmann-La Roche.

Furthest: phase 1, since Nov 9, 20222 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche21 open or runningphase 1since Nov 9, 2022Nov 9, 2022Sep 30, 2028phase 1 · NCT07107490
  • Named in Hoffmann-La Roche’s own pipeline as CHU clesitamig, phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2022First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT05619744 · 41 enrolled · United States, Denmark, Japan and more
  2. Jul 30, 2025Phase 1 study in Extensive Stage Small Cell Lung CancerNCT07107490 · 122 planned · Hong Kong, Japan, Taiwan

Ahead

  1. Sep 30, 2028Primary completion: phase 1 study in Extensive Stage Small Cell Lung CancerNCT07107490

TargetBeta

“A trispecific T-cell engager antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), the T-cell costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), and the T-cell surface antigen CD3, with potential immunostimulatin…”NCIt, read by Claude
“A trispecific T-cell engager antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), the T-cell costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), and the T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07107490Extensive Stage Small Cell Lung Cancer · Hong Kong, Japan, Taiwan1RecruitingSep 30, 2028122
NCT05619744Small Cell Lung Carcinoma · United States, Denmark, Japan and more1CompletedMar 4, 202541

How it is read

Names in the registry

  • “ALPS12”, 1 entry
  • “RO7616789”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.